-+ 0.00%
-+ 0.00%
-+ 0.00%

Castle Biosciences Q3 net loss widens to $4.1 million; Q3 revenue rises 24% to $102.9 million

PUBT·11/05/2026 21:36:50
Listen to the news
Castle Biosciences Q3 net loss widens to $4.1 million; Q3 revenue rises 24% to $102.9 million
  • Castle Biosciences’ third-quarter 2026 net loss widened to $4.1 million.
  • Revenue rose 24% year over year to $102.89 million.
  • TissueCypher test report volume climbed 47% year over year to 15,574.
  • Full-year 2026 revenue guidance increased to $385–395 million from $365–375 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611051605PR_NEWS_USPR_____DA89162) on November 05, 2026, and is solely responsible for the information contained therein.